The Top 2 Nuclear Energy Stocks to Buy Right Now

Uranium prices have rebounded to $86.35 per pound, with Citi seeing potential upside to $125 this year, supporting a stronger outlook for Cameco and the broader nuclear supply chain. Cameco expects 2025-2028 revenue and adjusted EBITDA CAGRs of 8% and 12%, while BWX Technologies reported 50% backlog growth to $7.3 billion and is projected to grow revenue and adjusted EBITDA at 13% and 12% CAGRs. The article is broadly constructive on both names, but valuation remains elevated at 33x and 30x this year's adjusted EBITDA.

Analysis

The cleanest read-through is that nuclear is shifting from a cyclical commodity trade to a constrained-capacity infrastructure trade. CCJ still has the better pure-beta to uranium pricing, but the bigger second-order winner may be BWXT because it sits closer to the bottlenecks that matter when the cycle matures: fuel fabrication, HALEU/TRISO, naval reactors, and SMR-adjacent component demand. That makes BWXT less exposed to spot volatility and more levered to multi-year order flow from utilities, defense, and data-center power buyers who care about schedule certainty more than commodity price.

The market is likely underappreciating how tight supply chains become when multiple demand pools hit at once. Rising uranium prices help miners immediately, but they also raise the hurdle rate for smaller developers and delay marginal projects, which can paradoxically extend the scarcity premium for incumbent producers like CCJ. Meanwhile, BWXT’s moat should widen if HALEU remains constrained, because regulatory approvals and manufacturing know-how become more important than headline reactor counts.

The main risk is that this becomes a “good story, expensive multiple” trade before it becomes an earnings compounding story. CCJ can rerate quickly on spot-price momentum, but its operating leverage cuts both ways if uranium normalizes or if utilities lock in long-term contracts below peak spot; BWXT’s multiple is more defensible, but any SMR enthusiasm disappointment would compress the growth premium. The time horizon matters: this is a 6-24 month re-rating trade if prices stay tight, but a 1-2 quarter pullback is very plausible if uranium spikes trigger profit-taking or if policy permitting slows new build announcements.

Consensus seems to be framing this as a simple AI-driven power shortage narrative, but the more durable angle is industrial national security. Defense demand gives BWXT a non-correlated earnings base, and that should help it outperform pure commercial nuclear names if macro growth rolls over. The market may be overpaying for near-term uranium scarcity while underpricing the option value of nuclear supply-chain monopolies that can compound even if the commodity cycle cools.

Key Decisions for Investors

• Long BWXT vs long CCJ as a pair trade over the next 6-12 months: BWXT offers lower commodity exposure, higher visibility backlog conversion, and better downside protection if uranium retraces; maintain a 1:1 notional start, add BWXT on any pullback if the pair cheapens.
• Use CCJ as the high-beta uranium expression for a 3-6 month momentum leg, but treat it as a trading position rather than core hold; take profits into sharp spot-price spikes or if the forward uranium curve flattens.
• Buy BWXT on weakness tied to SMR skepticism, with a 12-month target tied to backlog conversion rather than narrative; favorable risk/reward if the stock de-rates below its current growth multiple without a backlog reset.
• Consider a call spread on BWXT for the next 6-9 months to express upside from defense and nuclear supply-chain reacceleration while limiting multiple-compression risk.
• Avoid chasing broader nuclear baskets unless they include actual bottleneck assets; prefer firms with regulatory moats and contracted revenue over pure project-development exposure.